跳至主要内容
临床试验/JPRN-UMIN000014486
JPRN-UMIN000014486已完成未知

Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritis - Saitama East Study

Saitama East Study Group0 个研究点目标入组 100 人开始时间: 2014年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Patients have other rheumatic diseases. 2. Patients have malignant disorders in recent 5 years. 3.Patients have a risk for tuberculosis. 4.Patients who develpoprd bacterial infection and antibiotics were administrated within 30 days after first CPZ treatment. 5.Drug or alcohol addiction or abusers. 6.Patients who are not able to be adequately evaluated in this study. 7.Patients who have Type B viral hepatitis. 8.Patients who have nontuberculous mycobacteril infection. 9.Patients who have congestive heart failure(>II).

研究者

发起方
Saitama East Study Group

相似试验